Immune responses to human cancer stem-like cells/cancer-initiating cells

Cancer Science

Volumn 107, Issue 1, 2016, Pages 12-17

  Hirohashi, Yoshihiko ^a   Torigoe, Toshihiko ^a   Tsukahara, Tomohide ^a   Kanaseki, Takayuki ^a   Kochin, Vitaly ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cell; Cancer testis antigen; Cytotoxic T lymphocyte; Immunotherapy; Tumor antigen

Indexed keywords

CANCER TESTIS ANTIGEN; DIFFERENTIATION ANTIGEN; MELAN A; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PEPTIDE VACCINE; SURVIVIN; TRANSCRIPTION FACTOR SOX2; TUMOR ANTIGEN;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INITIATING CELL; CANCER STEM CELL; CANCER THERAPY; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; OVARY CANCER; PEPTIDE ANALYSIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SARCOMA; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; TRENDS;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84956595256     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12830     Document Type: Review

References (60)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
2. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-28.
3. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009; 17: 219-30.
4. Hirohashi Y, Torigoe T, Inoda S et al. The functioning antigens: beyond just as the immunological targets. Cancer Sci 2009; 100: 798-806.
5. Vacchelli E, Martins I, Eggermont A et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012; 1: 1557-76.
6. Hirohashi Y, Torigoe T, Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.
7. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
8. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6: 24.
9. Mizuguchi T, Torigoe T, Satomi F et al. Trials of vaccines for pancreatic ductal adenocarcinoma: is there any hope of an improved prognosis? Surg Today 2015; [Epub ahead of print].
10. Sato N, Hirohashi Y, Tsukahara T et al. Molecular pathological approaches to human tumor immunology. Pathol Int 2009; 59: 205-17.
11. Murase M, Kano M, Tsukahara T et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 2009; 101: 1425-32.
12. Nakatsugawa M, Takahashi A, Hirohashi Y et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 2011; 91: 1796-804.
13. Inoda S, Hirohashi Y, Torigoe T et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol 2011; 178: 1805-13.
14. Nishida S, Hirohashi Y, Torigoe T et al. Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay. J Urol 2012; 188: 294-9.
15. Nishizawa S, Hirohashi Y, Torigoe T et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012; 72: 2844-54.
16. Kuroda T, Hirohashi Y, Torigoe T et al. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One 2013; 8: e65158.
17. Yasuda K, Torigoe T, Morita R et al. Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One 2013; 8: e68187.
18. Michifuri Y, Hirohashi Y, Torigoe T et al. Small proline-rich protein-1B is overexpressed in human oral squamous cell cancer stem-like cells and is related to their growth through activation of MAP kinase signal. Biochem Biophys Res Commun 2013; 439: 96-102.
19. Hirohashi Y, Torigoe T, Inoda S, Morita R, Kochin V, Sato N. Cytotoxic T lymphocytes: sniping cancer stem cells. Oncoimmunology 2012; 1: 123-5.
20. Saijo H, Hirohashi Y, Torigoe T, Kochin V, Takahashi H, Sato N. Cytotoxic T lymphocytes: the future of cancer stem cell eradication? Immunotherapy 2013; 5: 549-51.
21. Hirohashi Y, Torigoe T, Inoda S et al. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy 2010; 2: 201-11.
22. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256: 139-89.
23. Mariya T, Hirohashi Y, Torigoe T et al. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer. Cancer Immunol Res 2014; 2: 1220-9.
24. Kitamura H, Torigoe T, Honma I et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 2006; 12: 4641-4.
25. Tsukahara T, Kawaguchi S, Torigoe T et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374-80.
26. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013; 31: 443-73.
27. Tallerico R, Todaro M, Di Franco S et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 2013; 190: 2381-90.
28. Wei J, Barr J, Kong LY et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010; 16: 461-73.
29. Di Tomaso T, Mazzoleni S, Wang E et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010; 16: 800-13.
30. Wu A, Wiesner S, Xiao J et al. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol 2007; 83: 121-31.
31. Schatton T, Schutte U, Frank NY et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010; 70: 697-708.
32. Busse A, Letsch A, Fusi A et al. Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? Clin Exp Metastasis 2013; 30: 781-91.
33. Volonté A, Di Tomaso T, Spinelli M et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol 2014; 192: 523-32.
34. Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck 2011; 33: 208-15.
35. Inoda S, Morita R, Hirohashi Y et al. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol 2011; 90: 55-60.
36. Morita R, Nishizawa S, Torigoe T et al. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci 2014; 105: 389-95.
37. Ahmed N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010; 16: 474-85.
38. Avril T, Vauleon E, Hamlat A et al. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 2012; 22: 159-74.
39. Gil EY, Jo UH, Lee HJ et al. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast Cancer Res Treat 2014; 147: 69-80.
40. Yao Y, Wang X, Jin K et al. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol 2008; 89: 121-9.
41. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135-46.
42. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
43. Yamada R, Takahashi A, Torigoe T et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 2013; 81: 428-34.
44. Takahashi A, Hirohashi Y, Torigoe T et al. Ectopically expressed variant form of sperm mitochondria-associated cysteine-rich protein augments tumorigenicity of the stem cell population of lung adenocarcinoma cells. PLoS One 2013; 8: e69095.
45. Boiko AD, Razorenova OV, van de Rijn M et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-7.
46. Dhodapkar KM, Feldman D, Matthews P et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci USA 2010; 107: 8718-23.
47. Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology 2013; 2: e25205.
48. Visus C, Wang Y, Lozano-Leon A et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin Cancer Res 2011; 17: 6174-84.
49. Jin F, Zhao L, Zhao HY et al. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 2008; 154: 541-50.
50. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun 2009; 9: 4.
51. Chung SS, Aroh C, Vadgama JV. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One 2013; 8: e83971.
52. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 2008; 68: 2419-26.
53. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74.
54. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-81.
55. Yadav M, Jhunjhunwala S, Phung QT et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515: 572-6.
56. Qin J, Liu X, Laffin B et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10: 556-69.
57. Kano M, Tsukahara T, Emori M et al. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci 2011; 102: 1443-7.
58. Xu Q, Liu G, Yuan X et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009; 27: 1734-40.
59. Ning N, Pan Q, Zheng F et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012; 72: 1853-64.
60. Vik-Mo EO, Nyakas M, Mikkelsen BV et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62: 1499-509.